Corvus Pharmaceuticals (NASDAQ:CRVS) Earns “Outperform” Rating from Oppenheimer

Corvus Pharmaceuticals (NASDAQ:CRVS)‘s stock had its “outperform” rating reissued by equities research analysts at Oppenheimer in a report released on Friday,Benzinga reports. They presently have a $33.00 target price on the stock, up from their previous target price of $32.00. Oppenheimer’s price objective would suggest a potential upside of 115.40% from the company’s current price.

CRVS has been the subject of several other reports. Barclays raised their price target on shares of Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, January 21st. Jefferies Financial Group increased their price objective on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. HC Wainwright lifted their price objective on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Mizuho set a $30.00 target price on Corvus Pharmaceuticals in a research report on Thursday, January 29th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Corvus Pharmaceuticals Trading Down 4.3%

Shares of Corvus Pharmaceuticals stock opened at $15.32 on Friday. The company’s 50-day moving average price is $16.46 and its 200-day moving average price is $10.57. Corvus Pharmaceuticals has a 12-month low of $2.54 and a 12-month high of $26.95. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -30.64 and a beta of 0.78.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, sell-side analysts predict that Corvus Pharmaceuticals will post -0.63 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CRVS. MPM Bioimpact LLC purchased a new position in shares of Corvus Pharmaceuticals during the fourth quarter worth approximately $21,126,000. State Street Corp boosted its stake in shares of Corvus Pharmaceuticals by 177.1% in the 4th quarter. State Street Corp now owns 2,788,223 shares of the company’s stock valued at $21,469,000 after purchasing an additional 1,781,904 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $5,754,000. Geode Capital Management LLC raised its position in Corvus Pharmaceuticals by 130.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,361,740 shares of the company’s stock worth $5,448,000 after purchasing an additional 771,454 shares during the period. Finally, DCF Advisers LLC purchased a new position in Corvus Pharmaceuticals in the 4th quarter worth $5,613,000. 46.64% of the stock is owned by hedge funds and other institutional investors.

Key Corvus Pharmaceuticals News

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $33 (from $32), implying substantial upside from current levels — a clear analyst vote of confidence that can support longer‑term buying interest. Oppenheimer Rating/Price Target
• Positive Sentiment: Company announced positive safety and efficacy data from cohort 4 of soquelitinib in a Phase 1 atopic dermatitis trial, including responses in patients with prior systemic therapy — this clinical progress materially de‑risks the program and supports future value for the pipeline. Atopic Dermatitis Trial Data
• Neutral Sentiment: Corvus released its Q4 2025 results and held an earnings call; management highlighted strategic advances tied to the pipeline and provided a business update, but the call materials are a mixed read for near‑term revenue prospects. Earnings Call Highlights
• Negative Sentiment: Q4 EPS came in at ($0.15), missing consensus by $0.01 — a small miss but enough to pressure sentiment in the absence of immediate revenue drivers; this likely contributed to the intraday pullback. Earnings Miss / Transcript
• Neutral Sentiment: Reported short‑interest updates in recent days show anomalous/zero values and appear unreliable — there is no clear evidence of a near‑term short squeeze or meaningful short pressure based on the published figures. (No actionable link available.)

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.